Can a genetic test choose the right chemo for pancreatic cancer?
Disease control
Recruiting now
This phase III trial tests whether a genetic signature can guide chemotherapy choice after surgery for pancreatic cancer. Patients are randomly assigned to receive either oxaliplatin-based or gemcitabine-based chemotherapy, chosen either by standard clinical criteria or by a tran…
Phase 3 • Sponsor: John Neoptolemos • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC